Pivotal data on major oncology drugs 'not being shared'

Researchers lament that a wealth of individual patient data that could inform future research are being withheld by industry

Less than half of the clinical trial data underpinning the approval of anticancer drugs are available for independent scrutiny despite an industry pledge for greater transparency, Australian and US researchers say.

Their audit of US regulatory approvals since 2011 shows that for three of the globally top-selling cancer drugs — nivolumab, pembrolizumab and pomalidomide — less than 10% of trial data were publicly available.

Nivolumab and pembrolizumab are the most expensive